Tag: Biocad

BIOCAD is Russia’s leading innovative biotechnology company which combines a world-class research and development center, ultra-modern pharmaceutical and biotechnology manufacturing facilities, and pre-clinical and clinical research infrastructure compliant with international standards.

BIOCAD is one of the few world’s full-cycle drug development and manufacturing companies, doing everything from new molecules discovery and genetic engineering to large-scale commercial manufacturing and marketing support. BIOCAD’s medicines are used to treat the most complex health conditions, such as cancer, HIV and Hepatitis C infections, multiple sclerosis and other disorders.

The company employs about 1000 people, 300 out of them scientists and researchers. In 2014 BIOCAD’s sales tripled and reached $200 million, while total amount of long-term international contracts exceeded half a billion US dollars. BIOCAD has subsidiaries in the US, Brazil, China, India, Singapore, and other countries.

BIOCAD has established a wide international presence – through a network of its subsidiaries and partnerships – in Belarus, Ukraine, Brazil, India, China and the United States. BIOCAD’s international strategy is to reinforce its own market leadership position in Russia while entering new markets, thus leveraging and balancing R&D, sales, procurement and logistic synergies across several continents. Every subsidiary or a partner company successfully combines R&D, market evaluation and business development activities, and provides access to talents, innovations and market opportunities of the region.

Biocad signs export contracts worth about $850 million

biocad
In 2018, Biocad, a pharmaceutical company, expects that its exports outside CIS will reach 1 billion rubles, said Alexey Torgov, Deputy General Director, on April 11 at a pharmaceutical forum held in St. Petersburg.

NatiVita plans to set up R&D centers in Belarus and Saint Petersburg

test tubes
Plans have been made to set up centers for developing personified vaccines in Belarus and Saint Petersburg, according to Aleksei Sychev, Chairman of the Board of Directors of the Belarusian pharmaceutical company NatiVita.

BIOCAD opens new laboratory to develop biologics

BIOCAD
BIOCAD, a biotech company, has opened a new lab in one of its R&D centers located in the village of Lyubuchany, Moscow region, where it plans to use unique technology to develop biological drugs.

BIOCAD leads the sales of anti-tumor drugs

BIOCAD
For January-December 2017, BIOCAD retains, for the second year in a row, the leadership in the segment of public budget procurement (by taking into account the data on all drugs) in ruble terms and in final prices.

Russia registers its first domestically manufactured biosimilar of infliximab

biocad
The Russian Ministry of Health has registered BCD-055, the first Russian-made biosimilar of infliximab developed by BIOCAD, a biotech company. BIOCAD was developing the local biosimilar of infliximab since 2013.

Russian biosimilar of adalimumab fully confirmed its equivalence

biocad
BIOСAD has successfully completed the main stage of clinical trials for the Russian biosimilar of adalimumab, a drug for the treatment of autoimmune and chronic inflammatory diseases

BIOCAD was allocated three land plots for a plant and preclinical studies center

biocad
BIOCAD received three land plots in the pharmaceutical cluster of Pushkinsky district in St. Petersburg

Russian pharma companies are registering medicines in more than 60 countries

tablets
When Pharma-2020 was launched in 2010, its first priority was to provide domestically manufactured medicines

BIOCAD launches drug manufacturing in North Africa

Biocad Morocco
BIOCAD and Sothema Labs announced that the medicines made under the technology provided by the Russian manufacturer will be launched in the North African market

BIOCAD will lower prices for strategically important drugs

biocad
BIOCAD, a biotech company, filed a set of documents to re-register the prices for a number of vital medicinal products in order to reduce them by 50-91%

Biocad plans to manufacture 22 new drugs at its new production site

biocad
Biocad will build a plant in Zelenograd Technology Development Special Economic Zone in Moscow, said Dmitry Morozov, the General Director of the company

BIOCAD wins a landmark patent dispute with Genentech

biocad
BIOCAD has won a dispute with Genentech on invalidating a patent for the use of rituximab

Russian biotechnology company BIOCAD prepares to enter the European market

biocad
The largest Russian biotechnology company BIOCAD plans to enter the European market with oncological and autoimmune medicines

BIOCAD will invest at least 3 billion rubles in a new production facility

biocad
BIOCAD, a biopharmaceutical company, will invest at least 3 billion rubles in the construction or upgrading of a pharmaceutical plant in Moscow

BIOСAD completes clinical trials of a biosimilar for anemia treatment

biocad
BIOСAD has completed the program of clinical trials for the first Russian-made darbepoetin alfa for the treatment of anemia in patients with chronic renal failure and oncological diseases

BIOCAD opens the Faculty of Molecular and Cell Biotechnology

research
On September 4, 2017, the students of the new Faculty began to attend their classes. This was preceded by a rigorous competitive selection, which revealed the best of the best.